Research Portal

Translin-Trax: Considerations for Oncological Therapeutic Targeting

Research output: Contribution to journal › Article › peer-review

Standard Standard

Translin-Trax: Considerations for Oncological Therapeutic Targeting. / McFarlane, Ramsay J.; Wakeman, Jane A.
In: Trends in Cancer, Vol. 6, No. 6, 06.2020, p. 450-453.

Research output: Contribution to journal › Article › peer-review

HarvardHarvard

McFarlane, RJ & Wakeman, JA 2020, 'Translin-Trax: Considerations for Oncological Therapeutic Targeting', Trends in Cancer, vol. 6, no. 6, pp. 450-453. https://doi.org/10.1016/j.trecan.2020.02.014

APA

McFarlane, R. J., & Wakeman, J. A. (2020). Translin-Trax: Considerations for Oncological Therapeutic Targeting. Trends in Cancer, 6(6), 450-453. https://doi.org/10.1016/j.trecan.2020.02.014

CBE

McFarlane RJ, Wakeman JA. 2020. Translin-Trax: Considerations for Oncological Therapeutic Targeting. Trends in Cancer. 6(6):450-453. https://doi.org/10.1016/j.trecan.2020.02.014

MLA

McFarlane, Ramsay J. and Jane A. Wakeman. "Translin-Trax: Considerations for Oncological Therapeutic Targeting". Trends in Cancer. 2020, 6(6). 450-453. https://doi.org/10.1016/j.trecan.2020.02.014

VancouverVancouver

McFarlane RJ, Wakeman JA. Translin-Trax: Considerations for Oncological Therapeutic Targeting. Trends in Cancer. 2020 Jun;6(6):450-453. Epub 2020 Mar 16. doi: 10.1016/j.trecan.2020.02.014

Author

McFarlane, Ramsay J. ; Wakeman, Jane A. / Translin-Trax: Considerations for Oncological Therapeutic Targeting. In: Trends in Cancer. 2020 ; Vol. 6, No. 6. pp. 450-453.

RIS

TY - JOUR

T1 - Translin-Trax: Considerations for Oncological Therapeutic Targeting

AU - McFarlane, Ramsay J.

AU - Wakeman, Jane A.

PY - 2020/6

Y1 - 2020/6

N2 - Dicer-deficient cancers have poor prognoses, which is linked to the degradation of tumour-suppressing miRNA precursors by the Translin-Trax (Tn-Tx) ribonuclease. Inhibition of Tn-Tx potentially offers a new therapeutic intervention point. However, Tn-Tx functions in an array of biological processes, and here we consider how this complexity could influence therapeutic design strategies.

AB - Dicer-deficient cancers have poor prognoses, which is linked to the degradation of tumour-suppressing miRNA precursors by the Translin-Trax (Tn-Tx) ribonuclease. Inhibition of Tn-Tx potentially offers a new therapeutic intervention point. However, Tn-Tx functions in an array of biological processes, and here we consider how this complexity could influence therapeutic design strategies.

KW - Translin-Trax

KW - Dicer

KW - drug development

KW - miRNA

KW - DNA repair

U2 - 10.1016/j.trecan.2020.02.014

DO - 10.1016/j.trecan.2020.02.014

M3 - Article

VL - 6

SP - 450

EP - 453

JO - Trends in Cancer

JF - Trends in Cancer

SN - 2405-8033

IS - 6

ER -